Electrocore Stock Price, News & Analysis

electroCore, Inc. (NASDAQ: ECOR) announced that its cofounder and Chief Medical Officer, Dr. Peter Staats, will receive a Lifetime Achievement Award at the American Society of Pain and Neuroscience Annual Conference on July 24th, 2021. This award recognizes Dr. Staats' significant contributions to pain medicine, including over 450 published works. He has held leadership roles in various medical societies and is currently the President Elect of the World Institute of Pain. electroCore focuses on non-invasive vagus nerve stimulation therapies for migraine and cluster headache treatment.

electroCore, Inc. (ECOR) expects approximately $1.3 million in revenue for Q2 2021, a 5% increase from Q1 2021 and a 69% growth year-over-year. The company reported a net cash usage of about $3.2 million for operations in the same period. As of June 30, 2021, cash and equivalents totaled approximately $23.7 million, which does not include $18.8 million raised in a recent offering. The company emphasizes ongoing operations and international expansion efforts.

electroCore, Inc. (Nasdaq: ECOR) will be presenting at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on July 14, 2021, at 3:30 PM. CEO Dan Goldberger will provide a comprehensive overview of the company and engage in one-on-one meetings. Interested parties can access the presentation through the provided webcast link.

Following the event, a replay will be available in the Investor section of electroCore's website. The company specializes in non-invasive vagus nerve stimulation therapies aimed at treating cluster headaches and migraines.

electroCore, Inc. (NASDAQ: ECOR) announced a public offering of 18 million shares at $1.00 each, raising approximately $18 million before expenses. The offering is expected to close around July 2, 2021. Underwriters have a 45-day option for an additional 2.7 million shares. Proceeds will support sales, marketing, working capital, and potential business expansions, although no specific acquisitions are currently planned. The offering is made under an effective shelf registration statement with the SEC.

electroCore, Inc. (NASDAQ: ECOR) announced a public offering of its common stock. The offering, which is subject to market conditions, aims to raise funds for sales, marketing, working capital, and potential acquisitions. The company will grant underwriters a 45-day option to purchase an additional 15% of shares. Ladenburg Thalmann & Co. Inc. is the sole book-runner, with Paulson Investment Company as co-manager. The offering will utilize an effective shelf registration statement filed with the SEC, and a preliminary prospectus will be available soon.

On June 10, 2021, electroCore, Inc. (Nasdaq: ECOR) announced the publication of a peer-reviewed study in Communications Biology highlighting the positive effects of non-invasive vagus nerve stimulation (nVNS) on cognitive performance in sleep-deprived Air Force personnel. The trial found that nVNS improved throughput capacity by 10% compared to a sham treatment, with lasting effects. This research opens avenues for nVNS in both military and civilian settings, addressing fatigue-related cognitive impairments. The findings suggest potential market growth for gammaCore's applications.

electroCore, Inc. (Nasdaq: ECOR) has partnered with Kromax International Corporation as the exclusive distributor of its gammaCore Sapphire™ non-invasive vagus nerve stimulator in Taiwan and China. This three-year agreement aims to enhance healthcare quality in pain management, particularly for migraine sufferers. The partnership is contingent on regulatory approvals, with the timing of these clearances currently uncertain. Both companies aim to improve patient outcomes through innovative healthcare solutions.

electroCore, a bioelectronic medicine company, will be added to the Russell Microcap Index effective June 28, 2021. This inclusion enhances the company's visibility to institutional investors and investment managers. The Russell Microcap Index tracks smaller market-cap companies and is part of FTSE Russell, which manages approximately $10.6 trillion in assets. CFO Brian Posner emphasized that being part of this index represents a significant opportunity for shareholder value.

electroCore, Inc. (Nasdaq: ECOR) has successfully sold $1.4 million in tax benefits through the New Jersey Economic Development Authority’s Technology Business Tax Certificate Transfer program for fiscal years 2019 and 2020. This sale enhances the company's balance sheet and bolsters its cash position, aiding in the commercialization of gammaCore and expansion of its non-invasive vagus nerve stimulation therapy. The program allows eligible companies to convert net operating losses into cash, thus supporting their growth objectives.